In recent years, studies on tumor models in vivo strongly indicate that the activated immune receptor NKG2D participates in the anti-cancer immune response, and it has also attracted much attention as a ligand of the NKG2D receptor (Smyth et al., 2005; Guerra et al., 2008; McGilvray et al., 2009). This evidence concerns the gene KLRK1 and neoplasm.